Solana Co quarterly report, Q2 FY2020

Full document

Business context and reporting period

This is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020—not a filing identified in its text as Solana Co. Helius develops non-invasive neurotechnology; its PoNS device was authorized for sale in Canada, while U.S., EU and Australian commercialization remained subject to regulatory clearance. Figures below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.

Financial performance and position

  • Revenue: Q2 revenue was $133,000, down from $518,000 a year earlier. First-half revenue was $339,000, versus $1.195 million. Most revenue was PoNS product sales; the filing attributes the declines partly to changes in the commercial arrangement and COVID-related clinic disruption.
  • Profit and margins: Q2 gross profit was $69,000 (about 52% gross margin), compared with $306,000 (about 59%) in Q2 2019. First-half gross profit was $174,000 (about 51%), versus $747,000 (about 63%). Q2 operating loss was $3.722 million and net loss was $3.361 million, compared with losses of $5.814 million and $186,000, respectively, in Q2 2019. First-half operating loss was $7.724 million and net loss was $8.118 million; the prior-year period reported an operating loss of $12.635 million and net income of $1.138 million.
  • Expenses and unusual earnings comparison: First-half R&D fell to $2.428 million from $4.956 million; SG&A fell to $5.255 million from $8.426 million. The 2019 first-half net income included a $13.837 million non-cash gain from derivative fair-value changes; the corresponding 2020 gain was only $3,000. 2020 also included $215,000 amortization, a $181,000 intangible-asset impairment, and a $110,000 loss on disposal of property and equipment.
  • Cash flow: First-half operating cash use was $6.979 million, an improvement from $11.214 million in 2019. Financing provided $6.727 million, principally from stock offerings, while investing provided $51,000. Cash declined $195,000 to $5.264 million from December 31, 2019.
  • Liquidity, debt and equity: Current assets were $6.743 million and current liabilities $2.027 million; reported working capital was $4.717 million, calculated excluding derivative instruments. Total liabilities were $2.308 million, including operating lease liabilities; the company reported no continuing PPP loan, having repaid the $323,000 loan in May 2020. Management said existing resources were expected to fund operations through Q3 2020 and disclosed substantial doubt about the company’s ability to continue as a going concern within one year after filing. First-half equity offerings brought in $7.233 million gross proceeds, net of $506,000 issuance costs. Shares outstanding increased from 30.7 million at year-end to 45.1 million at June 30.

Material changes, outlook and risks

  • Canadian sales and clinic activity were affected by COVID-19 clinic closures; reopening and patient return were uncertain. The pandemic also threatened clinical-trial timelines, regulatory work, supply, and access to capital.
  • Health Canada authorized PoNS for MS-related gait deficit in March 2020. The FDA granted Breakthrough Device designation for that indication in May; Helius submitted its U.S. de novo request on August 4, 2020, after quarter-end. For the traumatic brain injury indication, the planned TBI-002 study was temporarily suspended amid the pandemic. The EU application had been withdrawn; Australian regulatory responses were being prepared.
  • Helius reported that it had no assurance of raising additional capital on acceptable terms; failure to obtain funding could require reduced operations, asset sales, or cessation of operations. No formal revenue or earnings guidance was provided.
  • The company faced a Nasdaq minimum-bid-price deficiency, with a December 3, 2020 deadline to regain compliance. Delisting could impair share liquidity and access to capital. The shareholder class action was voluntarily dismissed without prejudice during Q2; the final dismissal order was signed July 1, 2020.
  • Other notable changes included a May 2020 office lease reduction, which generated a $56,000 gain, and an impairment-triggering COVID-19 assessment that concluded goodwill was not impaired at June 30.

Important facts for investors to verify

  1. Confirm the intended issuer: the supplied filing is for Helius Medical Technologies, Inc., not Solana Co.
  2. Assess the company’s near-term financing needs against its stated cash runway through Q3 2020 and going-concern warning.
  3. Track PoNS commercial revenue, clinic utilization and the effects of COVID-19 on Canadian treatment demand.
  4. Monitor FDA review and the timing, funding and restart of the TBI-002 trial, alongside Australian regulatory progress.
  5. Verify Nasdaq bid-price compliance and the potential dilution and warrant overhang from offerings and outstanding securities.